Trial reportPsychopharmacology2012
Acute and post-acute behavioral and psychological effects of salvinorin A in humans.
Trial report in Psychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Evaluation of the abuse potential of difelikefalin, a selective kappa-opioid receptor agonist, in recreational polydrug users.Clinical and translational science · 2022Trial
- Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans.The international journal of neuropsychopharmacology · 2016Trial
- Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.Current drug abuse reviews · 2014Trial
- Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects.Psychopharmacology · 2013Trial
- Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.Biological psychiatry · 2012Trial
- Kappa opioid receptor control of motivated behavior revisited.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- The Hallucinogen Rating Scale: Updated Factor Structure in a Large, Multistudy Sample.Biological psychiatry global open science · 2025Article
- Unveiling the Complexities of Medications, Substance Abuse, and Plants for Recreational and Narcotic Purposes: An In-Depth Analysis.Pharmacy (Basel, Switzerland) · 2025Review
- Emerging Psychotropic Drug for the Treatment of Trigeminal Pain: Salvinorin A.Pharmaceuticals (Basel, Switzerland) · 2024Review
- A Focused Review on Cognitive Improvement by the GenusPharmaceuticals (Basel, Switzerland) · 2023Review
- The Altered States Database: Psychometric data from a systematic literature review.Scientific data · 2022Article
- Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD.Psychopharmacology · 2022Article
- Models of psychedelic drug action: modulation of cortical-subcortical circuits.Brain : a journal of neurology · 2022Article
- The Kappa Opioid Receptor and the Sleep of Reason: Cortico-Subcortical Imbalance Following Salvinorin-A.The international journal of neuropsychopharmacology · 2022Article
- The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach.Handbook of experimental pharmacology · 2022Review
- The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies.Frontiers in pharmacology · 2022Review
- Dynorphin/Kappa-Opioid Receptor System Modulation of Cortical Circuitry.Handbook of experimental pharmacology · 2022Review
- Pharmacokinetics and Pharmacodynamics of Salvinorin A andPharmaceuticals (Basel, Switzerland) · 2021Review
- Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics.Journal of psychiatry and brain science · 2021Article
- The drug likeness analysis of anti-inflammatory clerodane diterpenoids.Chinese medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleSalvia divinorum has been used for centuries, and nontraditional use in modern societies is increasing. Inebriation and aftereffects of use are poorly documented in the scientific literature.
objectivesThis double-blind, placebo-controlled, randomized study analyzed subjective experiences of salvinorin A (SA) inebriation and consequences of use after 8 weeks.
methodsThirty middle-aged, well-educated, hallucinogen-experienced participants smoked either 1,017 or 100 μg SA 2 weeks apart in counterbalanced order. Vital signs were recorded before and after inhalation. A researcher rated participants' behavior during sessions. Participants completed the Hallucinogen Rating Scale (HRS) assessing inebriation immediately after each session. Differences were analyzed between groups as functions of dose and time. After 8 weeks, participants were interviewed to determine reported consequences and aftereffects.
resultsParticipants talked, laughed, and moved more often on an active dose. All six HRS clusters were significantly elevated on an active dose indicating hallucinogenic experiences. No significant adverse events were observed or reported by participants.
conclusionsThe present results indicate similarities as well as differences between the subjective effects of S. divinorum and other hallucinogens. As a selective kappa opioid receptor agonist, SA may be useful for expanding understanding of the psychopharmacology and psychology of hallucinogenic states beyond serotonergic mechanisms.
Indexed as
Identifiers
21901316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.